The store will not work correctly when cookies are disabled.
2-((pyridin-4-ylmethyl)amino)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one
ID: ALA5196898
PubChem CID: 168287220
Max Phase: Preclinical
Molecular Formula: C16H16N4OS
Molecular Weight: 312.40
This compound is available for customization.
Associated Items:
Names and Identifiers
Canonical SMILES: O=c1[nH]c(NCc2ccncc2)nc2sc3c(c12)CCCC3
Standard InChI: InChI=1S/C16H16N4OS/c21-14-13-11-3-1-2-4-12(11)22-15(13)20-16(19-14)18-9-10-5-7-17-8-6-10/h5-8H,1-4,9H2,(H2,18,19,20,21)
Standard InChI Key: BVKWYXYHZIWKHL-UHFFFAOYSA-N
Molfile:
RDKit 2D
22 25 0 0 0 0 0 0 0 0999 V2000
-3.7828 -0.2428 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.0682 0.1696 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.3539 -0.2428 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.3539 -1.0677 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.0682 -1.4802 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.7828 -1.0677 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.5693 -1.3227 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
-1.5693 0.0120 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0845 -0.6554 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.2338 0.7655 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.4133 0.8518 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.0714 0.1843 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.2640 -0.5692 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-1.6464 1.4802 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
0.8966 0.1843 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.3092 -0.5302 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.1345 -0.5302 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.5473 0.1842 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.3701 0.1835 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.7828 -0.5312 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
3.3735 -1.2431 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.5489 -1.2479 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
3 2 1 0
4 3 2 0
5 4 1 0
1 6 1 0
6 5 1 0
4 7 1 0
3 8 1 0
8 9 2 0
9 7 1 0
8 10 1 0
11 10 1 0
12 11 1 0
13 12 2 0
9 13 1 0
10 14 2 0
12 15 1 0
15 16 1 0
16 17 1 0
18 17 2 0
19 18 1 0
20 19 2 0
21 20 1 0
22 21 2 0
17 22 1 0
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 312.40 | Molecular Weight (Monoisotopic): 312.1045 | AlogP: 2.87 | #Rotatable Bonds: 3 |
Polar Surface Area: 70.67 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 2 |
#RO5 Violations: ┄ | HBA (Lipinski): 5 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: 10.91 | CX Basic pKa: 4.23 | CX LogP: 2.81 | CX LogD: 2.81 |
Aromatic Rings: 3 | Heavy Atoms: 22 | QED Weighted: 0.78 | Np Likeness Score: -1.98 |
References
1. Nizi MG, Maksimainen MM, Lehtiö L, Tabarrini O.. (2022) Medicinal Chemistry Perspective on Targeting Mono-ADP-Ribosylating PARPs with Small Molecules., 65 (11.0): [PMID:35608571] [10.1021/acs.jmedchem.2c00281] |